Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

A view of CEN Biotech's main facility in Lakeshore, Ontario, Saturday, December 6, 2014.

Geoff Robins/The Globe and Mail

CEN Biotech, a company that sought to open the world's largest medical marijuana facility in southern Ontario, has withdrawn its bid to challenge Health Canada in court.

The company asked for a judicial review after Health Canada informed CEN Biotech in February that its application for a licence was being rejected.

The move came after a series of concerns emerged about the company's conduct; including numerous different signatures attributed to its chief executive officer in regulatory documents; claims by CEN that it had ties to the Health Minister, which the Minister then disputed; and revelations that the company had invented the identity of an employee.

Story continues below advertisement

Health Canada issued a formal rejection of the company's licence on March 11. In a letter filed with the courts on Friday, CEN Biotech said it would not proceed with its application for a judicial review, and issued a notice of discontinuance, which was accepted by Health Canada.

Though some investors speculated on Friday that the withdrawal of the court challenge suggested the two sides might have reached a settlement, the government said that was never on the table.

"The judicial review application was withdrawn by CEN Biotech," a Health Canada spokesperson said in an e-mailed statement to The Globe and Mail.

"There was no settlement. The decision not to grant a license to CEN Biotech was not a negotiation, it was made by Health Canada Officials."

The move brings to a close CEN Biotech's efforts to secure a licence in Canada's recently privatized medical marijuana sector.

CEN's conduct came under scrutiny as the value of its shares soared last year amid false claims by the company that it had been licenced, or was on the verge of being licenced. CEN also told investors that it was partnering with Health Canada, which the department said was not true.

Many of those claims helped push up the stock price of CEN Biotech's parent company. At its height last year, the company was worth more than $350-million (U.S.) However, while such claims were being made to investors, CEN Biotech's CEO, Bill Chaaban, was selling off millions of shares at a significant profit.

Story continues below advertisement

CEN is the Canadian subsidiary of Creative Edge Nutrition, a Michigan-based nutritional supplements company that is traded as a penny stock on the loosely regulated over-the-counter (OTC) market in the United States.

This week, the Ontario Securities Commission said it is investigating the company, but did not comment further on its probe.

Mr. Chaaban could not be reached for comment Friday.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Comments are closed

We have closed comments on this story for legal reasons or for abuse. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies